<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168069">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781299</url>
  </required_header>
  <id_info>
    <org_study_id>PRO11020226</org_study_id>
    <nct_id>NCT01781299</nct_id>
  </id_info>
  <brief_title>Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU</brief_title>
  <official_title>Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relative performance and complication rates
      between the AlloDerm RTU and SurgiMend PRS products as well as the relative economics of
      these two treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, acellular dermal matrix (ADM) products have increasingly been utilized in
      breast reconstruction in order to protect the implant from exposure under a thin mastectomy
      skin flap while also allowing better control of the inframammary fold and, therefore, a
      better cosmetic result. In current clinical practice, cost is a factor in considering
      procedures and adjunct products. AlloDerm RTU and SurgiMend PRS are dissimilar in cost, with
      AlloDerm RTU more costly by 30-50%, and it is unclear if they are similar in efficacy.

      This study will be a prospective, randomized-to-test article (ADM), controlled,
      blinded-to-aesthetic/biopsy specimen evaluator trial. It will provide a way to assess the
      relative performance and complication rates between the AlloDerm RTU and SurgiMend PRS
      product as well as the relative economics of these two treatment options. Study subjects
      will only be randomized to one of two surgical mesh products. Patient information including
      age, BMI, smoking history, tumor size and location, preoperative bra cup size, mastectomy
      specimen weight, mastectomy method, plastic surgeon, mastectomy surgeon, quality of skin,
      tissue expander type and maximal volume, intra-operative fill volume, gel/saline implant
      type and size, chemotherapy, and radiation therapy will be summarized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>After first procedure: 10-14 days, then 2, 4, 6, and 10 weeks after drain removal; After second procedure: 1-2 weeks, 6 weeks, 1 year, and 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the overall complication rate for tissue expander breast reconstruction patients using SurgiMend PRS and AlloDerm RTU ADM products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Economic Evaluation</measure>
    <time_frame>End of Study Participation</time_frame>
    <safety_issue>No</safety_issue>
    <description>At the completion of the Aesthetic Evaluation records will be evaluated to ascertain the overall cost of ADMs used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic Evaluation</measure>
    <time_frame>6 weeks, 1 year, and 3 years following permanent implant placement.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Initial aesthetic evaluation will occur at approximately 6 weeks after permanent implant placement. Re-evaluation will occur at 1 and 3 years following permanent implant placement. This will involve physical examination, 2D photographs, and patient Breast-Q self-examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ADM Biopsy</measure>
    <time_frame>Approximately 12 weeks after ADM implantation (at time of second operative procedure)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biopsies are taken at time of permanent implant placement. A semi-quantitative scoring system will be used to evaluate histological characteristics, such as capsule formation, inflammation, presence of polymorphonuclear cells, giant cells, plasma cells and/or degradation of material.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>AlloDerm RTU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SurgiMend PRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AlloDerm RTU</intervention_name>
    <arm_group_label>AlloDerm RTU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SurgiMend PRS</intervention_name>
    <arm_group_label>SurgiMend PRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject's with ability to provide informed consent.

          2. Subjects greater than 18 years old

          3. Subjects to undergo an immediate tissue expander reconstruction following mastectomy;
             and

          4. Subjects who are, in the opinion of the Investigator, able to understand the study,
             comply with the study design and are willing to return to the clinic for all the
             research required follow-up visits.

        Exclusion Criteria:

          1. Subjects less than 18 years of age

          2. Subjects that based on surgeon's discretion cannot be effectively reconstructed with
             the use of ADM product

          3. Pregnancy

          4. Bovine allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Shestak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter W Adams, BS</last_name>
    <phone>412-864-2582</phone>
    <email>adamsp3@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Center for Innovation in Restorative Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter W Adams, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Afrooz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Autumn Aul, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Bliley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Spencer Brown, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn De La Cruz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Gimbel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlynn Graves, BS, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Kling</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kacey Marra, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Martin, RN, BSN, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy McCormick, MS, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenelle Mock, RN, BSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vu Nguyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J. Peter Rubin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patsy Simon, RN, BS, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Snyder, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wendy Wakefield, CRNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg. 2005 Sep;55(3):232-9.</citation>
    <PMID>16106158</PMID>
  </reference>
  <reference>
    <citation>Gamboa-Bobadilla GM. Implant breast reconstruction using acellular dermal matrix. Ann Plast Surg. 2006 Jan;56(1):22-5.</citation>
    <PMID>16374090</PMID>
  </reference>
  <reference>
    <citation>Topol BM, Dalton EF, Ponn T, Campbell CJ. Immediate single-stage breast reconstruction using implants and human acellular dermal tissue matrix with adjustment of the lower pole of the breast to reduce unwanted lift. Ann Plast Surg. 2008 Nov;61(5):494-9. doi: 10.1097/SAP.0b013e31816d82d9.</citation>
    <PMID>18948774</PMID>
  </reference>
  <reference>
    <citation>Maxwell GP, Gabriel A. Possible future development of implants and breast augmentation. Clin Plast Surg. 2009 Jan;36(1):167-72, viii. doi: 10.1016/j.cps.2008.08.005.</citation>
    <PMID>19055971</PMID>
  </reference>
  <reference>
    <citation>Stump A, Holton LH 3rd, Connor J, Harper JR, Slezak S, Silverman RP. The use of acellular dermal matrix to prevent capsule formation around implants in a primate model. Plast Reconstr Surg. 2009 Jul;124(1):82-91. doi: 10.1097/PRS.0b013e3181ab112d.</citation>
    <PMID>19568048</PMID>
  </reference>
  <reference>
    <citation>Namnoum JD. Expander/implant reconstruction with AlloDerm: recent experience. Plast Reconstr Surg. 2009 Aug;124(2):387-94. doi: 10.1097/PRS.0b013e3181aee95b.</citation>
    <PMID>19644253</PMID>
  </reference>
  <reference>
    <citation>Grabov-Nardini G, Haik J, Regev E, Winkler E. AlloDerm Sling for Correction of Synmastia After Immediate, Tissue Expander, Breast Reconstruction in Thin Women. Eplasty. 2009 Nov 12;9:e54.</citation>
    <PMID>20011582</PMID>
  </reference>
  <reference>
    <citation>Sbitany H, Sandeen SN, Amalfi AN, Davenport MS, Langstein HN. Acellular dermis-assisted prosthetic breast reconstruction versus complete submuscular coverage: a head-to-head comparison of outcomes. Plast Reconstr Surg. 2009 Dec;124(6):1735-40. doi: 10.1097/PRS.0b013e3181bf803d.</citation>
    <PMID>19952627</PMID>
  </reference>
  <reference>
    <citation>Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. Plast Reconstr Surg. 2009 Dec;124(6):1743-53. doi: 10.1097/PRS.0b013e3181bf8087.</citation>
    <PMID>19952629</PMID>
  </reference>
  <reference>
    <citation>Chun YS, Verma K, Rosen H, Lipsitz S, Morris D, Kenney P, Eriksson E. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. Plast Reconstr Surg. 2010 Feb;125(2):429-36. doi: 10.1097/PRS.0b013e3181c82d90.</citation>
    <PMID>20124828</PMID>
  </reference>
  <reference>
    <citation>Lanier ST, Wang ED, Chen JJ, Arora BP, Katz SM, Gelfand MA, Khan SU, Dagum AB, Bui DT. The effect of acellular dermal matrix use on complication rates in tissue expander/implant breast reconstruction. Ann Plast Surg. 2010 May;64(5):674-8. doi: 10.1097/SAP.0b013e3181dba892.</citation>
    <PMID>20395795</PMID>
  </reference>
  <reference>
    <citation>Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009 Aug;124(2):345-53. doi: 10.1097/PRS.0b013e3181aee807. PubMed PMID: 19644246.</citation>
    <PMID>19644246</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 6, 2013</lastchanged_date>
  <firstreceived_date>January 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ken Shestak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Immediate reconstruction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
